-
公开(公告)号：US20160058716A1
公开(公告)日：2016-03-03
申请号：US14852236
申请日：2015-09-11
IPC分类号： A61K31/137 , A61K9/48 , A61K9/16 , A61K9/00
CPC分类号： A61K9/2054 , A61J3/10 , A61K8/731 , A61K9/0002 , A61K9/0053 , A61K9/006 , A61K9/0095 , A61K9/06 , A61K9/08 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/19 , A61K9/20 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2095 , A61K9/28 , A61K9/2806 , A61K9/2813 , A61K9/284 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K9/2893 , A61K9/48 , A61K9/4808 , A61K9/4833 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K9/4875 , A61K9/4891 , A61K9/5047 , A61K9/5078 , A61K9/5089 , A61K9/70 , A61K31/137 , A61K31/167 , A61K31/192 , A61K31/439 , A61K31/4458 , A61K31/48 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/08 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/26 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38
摘要： Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
-
公开(公告)号：US08361499B2
公开(公告)日：2013-01-29
申请号：US13535996
申请日：2012-06-28
IPC分类号： A61K9/48 , A61K31/485 , A61K9/00 , A61K9/20 , A61K31/616 , A61P29/00
CPC分类号： A61K31/485 , A61K9/0004 , A61K9/0053 , A61K9/141 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2072 , A61K9/2077 , A61K9/2086 , A61K31/194 , A61K31/46
摘要： A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.
-
公开(公告)号：US20130011543A1
公开(公告)日：2013-01-10
申请号：US13603813
申请日：2012-09-05
IPC分类号： B05D5/00
CPC分类号： A61K9/5026 , A61K9/2081 , A61K31/485
摘要： A method for preparing a solid oral dosage form comprising up to about 160 mg of oxycodone or a salt thereof to control pain in substantially all patients is disclosed. The method comprises forming spheroids comprising a spheronising agent and oxycodone or a salt thereof, and coating the spheroids with a controlled-release film coat. Repeated “q12h” (i.e., every 12 hour) administration of the dosage form through steady-state conditions results in a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after administration.
摘要翻译： 公开了一种制备固体口服剂型的方法，其包含至多约160mg的羟考酮或其盐以控制基本上所有患者的疼痛。 该方法包括形成包含球形化剂和羟考酮或其盐的球体，并用控释膜包衣涂覆球体。 通过稳态条件重复给药剂量q12h（即每12小时）导致给予后平均约2至约4.5小时的羟考酮的平均最大血浆浓度高达约240ng / ml， 在给药后约10至约14小时，平均最小血浆浓度高达约120ng / ml。
-
4.发明申请公开(公告)号：US20120288567A1
公开(公告)日：2012-11-15
申请号：US13535605
申请日：2012-06-28
IPC分类号： A61K31/485 , A61P29/00 , A61K9/14
CPC分类号： A61K9/2077 , A61K9/14 , A61K9/1635 , A61K9/1647 , A61K9/167 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2081 , A61K9/2086 , A61K9/5026 , A61K9/5078 , A61K9/5084 , A61K31/44 , A61K31/445 , A61K31/46 , A61K31/485 , A61K45/06 , A61K47/32 , A61K47/38 , A61K2300/00
摘要： Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.
摘要翻译： 公开了口服剂型，其包含（i）治疗有效量的阿片样物质激动剂; （ii）可释放形式的阿片拮抗剂; 和（iii）当所述剂型完整施用时不释放的螯合阿片样物质拮抗剂及其方法。
-
5.发明授权公开(公告)号：US08231901B2
公开(公告)日：2012-07-31
申请号：US13043134
申请日：2011-03-08
IPC分类号： A61K9/20
CPC分类号： A61K9/2077 , A61K9/14 , A61K9/1635 , A61K9/1647 , A61K9/167 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2081 , A61K9/2086 , A61K9/5026 , A61K9/5078 , A61K9/5084 , A61K31/44 , A61K31/445 , A61K31/46 , A61K31/485 , A61K45/06 , A61K47/32 , A61K47/38 , A61K2300/00
摘要： Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.
摘要翻译： 公开了口服剂型，其包含（i）治疗有效量的阿片样物质激动剂; （ii）可释放形式的阿片拮抗剂; 和（iii）当所述剂型完全施用时不释放的螯合阿片样物质拮抗剂及其方法。
-
公开(公告)号：US08142811B2
公开(公告)日：2012-03-27
申请号：US12378586
申请日：2009-02-17
CPC分类号： A61K31/485 , A61K9/0004 , A61K9/0053 , A61K9/141 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2072 , A61K9/2077 , A61K9/2086 , A61K31/194 , A61K31/46
摘要： A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.
摘要翻译： 公开了一种固体口服释放剂型的氢可酮，所述剂型包含镇痛有效量的氢可酮或其药学上可接受的盐，以及控释材料。
-
7.发明申请PHARMACEUTICAL FORMULATIONS CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT 有权含有OPIOID AGONIST，OPIOID ANTAGONIST和胶凝剂的药物制剂公开(公告)号：US20110230510A1
公开(公告)日：2011-09-22
申请号：US12909527
申请日：2010-10-21
IPC分类号： A61K31/485 , A61P25/04 , A61P25/36
CPC分类号： A61K31/485 , A61K9/0053 , A61K9/1635 , A61K9/1647 , A61K9/2027 , A61K9/205 , A61K9/2081 , A61K9/5078 , A61K47/10 , A61K47/32 , A61K47/36
摘要： Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.
摘要翻译： 在某些实施方案中公开的是口服剂型，其包含治疗有效量的阿片类止痛剂，阿片样物质拮抗剂和一种或多种药学上可接受的赋形剂; 所述剂型还包括有效量的胶凝剂，以使得不适于施用的粘度，所述粘度选自肠胃外和鼻内施用于当所述剂型粉碎时形成的溶解混合物，并与约0.5至约10ml 的水性液体。
-
公开(公告)号：US20110104214A1
公开(公告)日：2011-05-05
申请号：US12917148
申请日：2010-11-01
申请人： Benjamin Oshlack , Curtis Wright , Derek Prater
发明人： Benjamin Oshlack , Curtis Wright , Derek Prater
IPC分类号： A61K31/485 , A61K9/00 , A61P25/04
CPC分类号： A61K31/485 , A61K9/0004 , A61K9/1617 , A61K9/1635 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2086
摘要： The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
摘要翻译： 本发明涉及含有羟考酮或其药学上可接受的盐的持续释放制剂，其在稳定状态下口服给予患者及其方法时，其平均C24 / Cmax羟考酮比例为0.6至1.0或0.7至1。
-
公开(公告)号：US20110097404A1
公开(公告)日：2011-04-28
申请号：US12909614
申请日：2010-10-21
申请人： Benjamin Oshlack , Curtis Wright , J. David Haddox
发明人： Benjamin Oshlack , Curtis Wright , J. David Haddox
IPC分类号： A61K9/16 , A61K31/4355
CPC分类号： A61K9/5084 , A61K9/0043 , A61K9/0053 , A61K9/006 , A61K9/02 , A61K9/14 , A61K9/1617 , A61K9/1635 , A61K9/1647 , A61K9/1676 , A61K9/1694 , A61K9/2077 , A61K9/2081 , A61K9/2866 , A61K9/4808 , A61K9/50 , A61K9/501 , A61K9/5015 , A61K9/5026 , A61K9/5031 , A61K9/5078 , A61K9/51 , A61K9/7053 , A61K9/7061 , A61K31/485
摘要： Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.
摘要翻译： 公开了一种口服剂型，其包含（i）可释放形式的阿片样物质激动剂和（ii）当剂型口服完整时不释放的螯合阿片样物质拮抗剂。
-
公开(公告)号：US20090148517A1
公开(公告)日：2009-06-11
申请号：US12372460
申请日：2009-02-17
申请人： Benjamin Oshlack , Mark Chasin , Hun-Pin Huang
发明人： Benjamin Oshlack , Mark Chasin , Hun-Pin Huang
IPC分类号： A61K9/14 , A61K31/485 , A61K9/52 , B29B9/00 , A61P25/04
CPC分类号： A61K9/1635 , A61K9/145 , A61K9/1617 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2027 , A61K9/2077 , A61K9/2081 , A61K9/2095 , B29B9/06 , Y10S514/951 , Y10S514/962
摘要： A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length of from about 0.1 to about 12 mm and can be of varying diameters and each unit dose provides a release of therapeutically active agents over at least about 8 hours. Methods of preparing the unit doses as well as extrusion processes and methods of treatment are also disclosed.
摘要翻译： 公开了包含多个熔融挤出颗粒的单位剂量持续释放口服剂型，每个主要由治疗活性剂，一种或多种阻滞剂和任选的水不溶性粘合剂组成。 颗粒具有约0.1至约12mm的长度，并且可以具有不同的直径，并且每个单位剂量在至少约8小时内提供治疗活性剂的释放。 还公开了制备单位剂量的方法以及挤出方法和治疗方法。
-
-
-
-
-
-
-
-
-
搜索结果
124 条记录 (耗时 0.037 秒)